Axogen is focused on the science, development and commercialization of technologies for peripheral nerve regeneration and repair. Co.'s platform for peripheral nerve repair features a portfolio of products, including Avance® Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed peripheral nerves without the comorbidities associated with a second surgical site; and Axoguard® Nerve Connector, a porcine submucosa extracellular matrix coaptation aid for tensionless repair of severed peripheral nerves. Co. also provides Axotouch® Two-Point Discriminator, which is used to measure the innervation density of any surface area of the skin. The AXGN stock yearly return is shown above.
The yearly return on the AXGN stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2020 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the AXGN annual return calculation with any dividends reinvested as applicable (on ex-dates).
|